Abstract
The aim is to study the levels of antiphospholipid (aPL) and antineutrophil antibodies in men with stable coronary heart disease (CHD) with postinfarction cardiosclerosis and to evaluate its relationship with the disease manifestation. Materials and methods: 164 men with stable CHD and postinfarction cardiosclerosis (53.0 ± 9.14 (M ± σ) years) and 48 age-matched men without CHD were examined. The total aPL IgG and IgM, beta-2 glycoprotein 1 antibodies (anti-β2-GP 1) IgG and IgM, and antibodies for neutrophil proteinase-3 / myeloperoxidase (anti-PR3 / MPO) IgG were determined by ELISA. Results: Positive levels of aPL and anti-β2-GP 1 of IgG were identified in 56.7% (33.5% double positivity of aPL + anti-β2-GP 1) and 29.2% of control group (p < 0.001), while the IgM was lower (11.6% vs. 6.2%, p = 0.55, respectively). Significantly higher (1.5-1.7 times) levels of aPL and anti-β2-GP 1 were identified in patients who underwent myocardial infarction (MI) aged less than 44 years, after Q-MI, recurrent MI, in the presence of ischemic stroke, livedo reticularis. In 6.7% of patients with positive levels of aPL and anti-β2-GP 1 low IgG anti-PR3 / MPO levels were detected. Conclusions: In men with postinfarction cardiosclerosis, IgG positivity according to total aPL and anti-β2-GP 1 is associated with a higher incidence of Q-MI and with recurrent MI. Men with postinfarction cardiosclerosis have a tendency to increase anti-PR3 / MPO levels of IgG under conditions of double aPL positivity and anti-β2-GP1 of IgG.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.